Missing: NanoCor Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: NanoCor Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing NanoCor Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
NanoCor Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
NanoCor Therapeutics Patents
NanoCor Therapeutics has filed 1 patent.
RNA interference, RNA, MicroRNA, Gene expression, Molecular biology
RNA interference, RNA, MicroRNA, Gene expression, Molecular biology
Latest NanoCor Therapeutics News
Feb 5, 2020
Share 7 mins ago Asklepios BioPharmaceutical (AskBio) and its subsidiary NanoCor Therapeutics have dosed the first patient in a Phase I clinical trial of gene therapy candidate NAN-101 to treat congestive heart failure. Congestive heart failure is characterised by the inability of the heart to supply the necessary blood and oxygen to the body. The condition lacks cure, while drugs and surgical therapy are intended to alleviate symptoms and slow damage. NAN-101 is an adeno-associated virus (AAV) gene therapy designed to stimulate protein phosphatase inhibitor 1 (I-1c) to block the action of protein phosphatase 1 (PP1), which is linked to heart failure. The medication is directly given to the heart via an intracoronary infusion. The NAN-CS101 open-label, dose-escalation, multi-centre trial will evaluate three doses of the gene therapy in approximately 12 patients with NYHA Class III heart failure. The primary objective of the study is safety, along with the effect of NAN-101 on patient health, which is tracked as changes in exercise capacity, heart function, and quality of life. AskBio chief scientific officer and co-founder Jude Samulski said: “Dosing the first patient using gene therapy to target I-1c to improve heart function is a tremendous milestone not only for the AskBio and NanoCor teams but, more importantly, for patients whose quality of life is negatively affected by CHF. “We initially developed this gene therapy as treatment for late-stage Duchenne muscular dystrophy patients who typically die from cardiomyopathy. Following preclinical studies, we observed that heart function improved, which led us to investigate treatment for all types of heart failure.” The Phase I trial is expected to be completed in July next year. What you should read next
NanoCor Therapeutics Frequently Asked Questions (FAQ)
When was NanoCor Therapeutics founded?
NanoCor Therapeutics was founded in 2005.
Where is NanoCor Therapeutics's headquarters?
NanoCor Therapeutics's headquarters is located at 870 Martin Luther King Junior Boulevard, Chapel Hill.
What is NanoCor Therapeutics's latest funding round?
NanoCor Therapeutics's latest funding round is Unattributed - II.
How much did NanoCor Therapeutics raise?
NanoCor Therapeutics raised a total of $6.25M.
Who are the investors of NanoCor Therapeutics?
Investors of NanoCor Therapeutics include Medtronic.
Who are NanoCor Therapeutics's competitors?
Competitors of NanoCor Therapeutics include Bloomage BioTech, Zymeworks, Dendreon, Cebix, Tau Therapeutics and 10 more.
Compare NanoCor Therapeutics to Competitors
Recoly N.V., a Netherlands Antilles based biotechnology company, is in the business of developing or acquiring platform technologies for use in the health care industry. Through the efforts of its research and development team, Recoly has developed a patented, platform technology which has been shown to prolong the half-life and improve the biological efficacy of protein and peptide pharmaceuticals by formulating them with PEGylated liposomes. The proteins and peptides bind non-covalently and yet with high affinity to the external surface of the liposomes; the proteins and peptides maintain their biological activity. No change in the protein/peptide manufacturing process is required. Recoly's business model is to partner with pharmaceutical and biotechnology companies to develop improvements of approved pharmaceutical products and thereby extend product franchises and enlarge product pipelines.
Norgen Biotek Corp. is a biotechnology company focusing principally on advancing sample preparation products for nucleic acid (DNA & RNA) and protein purification, clean-up and concentration. Norgen has one platform technology with many applications based on a resin that can be applied in the purification of DNA, RNA and proteins. The uniqueness and novelty of this technology has been recognized by the National Research Council through awarding Norgen the prestigious "Innovation Leader Award for 2003". The company holds more than a dozen issued patents and several others are pending. Norgen currently manufactures over 40 products that are used by researchers working in genomics and proteomics in academia, pharma/biotech companies, and government institutions.
ATNT is a biotech company which develops cross-disciplinary engineering methods, to find the most effective molecular targets for treatment of complex human disorders.
Synaptic Research LLC is a biotechnology company which conducts research and develops products based on naturally-occurring large protein molecules. Specifically, the company engineers proteins derived from toxins which affect the synaptic junction. A well-known example of such a protein is the Botulinum Neurotoxin, or BoNT. This protein has qualities of targeting and persistence which make it an excellent candidate for further engineering and development of therapeutic and pharmaceutical products.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
SemBioSys Genetics Inc is a biotechnology company focused on the development commercialization and production of protein-based pharmaceuticals and nonpharmaceutical products based on our plant genetic engineering skills and our proprietary oilbodyoleosin technology platform, the Stratosome Biologic System
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.